Text Size
Trial record 10 of 51 for:    "Graves Disease"
Previous Study | Return to List | Next Study

Genetic Polymorphisms Associated With Cigarette Smoking and Risk of Graves’ Disease

This study has been completed.
Sponsor:
Collaborator:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Information provided by:
University of Campinas, Brazil
ClinicalTrials.gov Identifier:
NCT00505011
First received: July 18, 2007
Last updated: July 19, 2007
Last verified: July 2007
History of Changes
  Purpose

Cigarette smoking is a well-recognized risk factor of Graves’ disease and, particularly, Graves’ ophthalmopathy. Hence, germline polymorphisms of detoxification genes and genes belonging to the major DNA repair/apoptosis pathways might have an important role in disease susceptibility. In addition, as some of these genes are regulated by thyroid hormones, they could affect the outcome of these patients. Our objective was to assess the influence of the GST, CYP and TP53 gene polymorphisms in the risk of Graves' disease and its outcome.


Condition
Graves' Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Retrospective/Prospective
Official Title: Study of the Influence of the GST, CYP and TP53 Gene Polymorphisms in the Risk of Graves' Disease and Its Outcome.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Campinas, Brazil:

Enrollment: 1998
Study Start Date: February 1998
Study Completion Date: February 2007
Detailed Description:

Although the role of many polymorphisms of genes related to toxins’ metabolism has been extensively investigated regarding the susceptibility to thyroid cancer, their influence in thyroid autoimmune diseases risk is still largely unknown. Hence, this study was designed to assess the influence of GSTT1, GSTM1, GSTP1, CYP1A1 and 72TP53 polymorphic inheritance on the susceptibility to Graves' disease and to its response to the treatment.

  Eligibility

Ages Eligible for Study:   2 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Graves' disease patients
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00505011

Sponsors and Collaborators
University of Campinas, Brazil
Fundação de Amparo à Pesquisa do Estado de São Paulo
Investigators
Principal Investigator: Laura S Ward, MD, PhD State University of Campinas- UNICAMP
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00505011     History of Changes
Other Study ID Numbers: 17072007
Study First Received: July 18, 2007
Last Updated: July 19, 2007
Health Authority: Brazil: National Committee of Ethics in Research

Keywords provided by University of Campinas, Brazil:
susceptibility
genes
environment
ophthalmopathy
outcome

Additional relevant MeSH terms:
Graves Disease
Exophthalmos
Orbital Diseases
Eye Diseases
Goiter
 Thyroid Diseases
Endocrine System Diseases
Hyperthyroidism
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on May 16, 2013